Expanding Product Offerings in Priority Areas through Active Licensing
First written in FY2017-Q2. 15 of 27 entries say "Advanced", first in FY2018. Latest entry: FY2026.
The whole theme swung hardest in 2025: 1 of 11 companies on the "Worse" side.
1 other company's latest entry also says "Achieved".
- FY2026AchievedAnnual report
「We pursued activities by allocating financial and human resources to the fullest extent to expand the development pipeline through in-licensing, and acquired 7 products, exceeding the target of 6.」
Regarding the pipeline expansion through in-licensing set out in Stage 1, we acquired 7 products against a target of 6, exceeding the target. - FY2026-H1AdvancedAnnual report
「In September 2025, we entered into a co-development and license agreement with Hinge Bio for novel drug candidates for SLE and other indications in Japan.」
Under the policy of treating development pipeline expansion through in-licensing as our highest priority, efforts progressed to the execution of a joint development and license agreement in Japan with Hinge Bio. - FY2025AdvancedAnnual report
「To expand the pipeline, we established a Business Development Division in fiscal 2023 to strengthen our ability to acquire in-licensed products, reformed the organization, and expanded and deployed human resources. To acquire new in-licensed products, we worked not only to expand the modalities and disease areas targeted for in-licensing, but also to improve the speed of product evaluation and acquisition.」
Efforts to expand the development pipeline through in-licensing took concrete form after the establishment of the Business Development Division, including expansion of the target modalities and disease areas, faster evaluation and acquisition, and the expansion and deployment of human resources. - FY2025-H1RestatedAnnual report
「We have also positioned expansion of the development pipeline through in-licensing as our highest priority. By allocating financial and human resources to the fullest extent, we are strengthening our licensing and alliance capabilities and pursuing activities aimed at expanding the development pipeline at an early stage.」
We continue to treat expansion of the development pipeline through in-licensing as our highest priority, investing financial and human resources and strengthening our licensing and alliance capabilities. - FY2024AdvancedAnnual report
「We established a Business Development Division to strengthen our ability to acquire in-licensed products, reformed the organization, and expanded and deployed human resources.」
Efforts to expand the development pipeline through in-licensing took concrete form in the establishment of a Business Development Division, organizational reform, and the expansion and deployment of human resources. At the same time, the company stated that no new in-licensing agreement had been concluded in fiscal 2023. - FY2024-Q3RestatedAnnual report
「We have also positioned expansion of the development pipeline through in-licensing as our highest priority. By allocating financial and human resources to the fullest extent, we are strengthening our licensing and alliance capabilities and pursuing activities aimed at expanding the development pipeline at an early stage.」
We continue to treat pipeline expansion through in-licensing as our highest priority, investing financial and human resources and strengthening our licensing and alliance capabilities. - FY2024-Q2RestatedAnnual report
「We have also positioned expansion of the development pipeline through in-licensing as our highest priority. By allocating financial and human resources to the fullest extent, we are strengthening our licensing and alliance capabilities and pursuing activities aimed at expanding the development pipeline at an early stage.」
We continue to treat pipeline expansion through in-licensing as our highest priority, investing financial and human resources and strengthening our licensing and alliance capabilities. - FY2024-Q1RaisedAnnual report
「We have also positioned expansion of the development pipeline through in-licensing as our highest priority. By allocating financial and human resources to the fullest extent, we are strengthening our licensing and alliance capabilities and pursuing activities aimed at expanding the development pipeline at an early stage.」
We have positioned pipeline expansion through in-licensing as our highest priority, explicitly committing to maximum allocation of financial and human resources and strengthening our licensing and alliance capabilities, thereby placing greater emphasis on it than before. - FY2023-Q3AdvancedAnnual report
「In expanding its development pipeline during the third quarter of the fiscal year, Kyorin Pharmaceutical Co., Ltd. entered into an agreement with Susemed Co., Ltd. in November 2022 for the joint research and development and sale of a therapeutic app in the field of otolaryngology.」
Expansion of the pipeline through partnering activities took concrete form in a joint research, development and commercialization agreement with SusMed for a therapeutic app in the ear, nose and throat field. - FY2023-Q1AdvancedAnnual report
「To expand the development pipeline, Kyorin Pharmaceutical Co., Ltd. entered into a joint development and license agreement in May 2022 with CellGentek Co., Ltd. (head office: Chiba, Chiba Prefecture) concerning regenerative medical products using genetically modified human adipocytes for the treatment of Fabry disease.」
Expansion of the product and development pipelines through partnering took concrete form in the joint development and license agreement with CellGentek. - FY2022-Q3AdvancedAnnual report
「In domestic and overseas development during the third quarter of the fiscal year, MSD, the originator of the selective P2X3 receptor antagonist and cough treatment Rifanua Tablets 45 mg, with gefapixant citrate as its generic name, obtained marketing approval. Kyorin Pharmaceutical Co., Ltd. had entered into an agreement to acquire exclusive marketing rights in Japan for the product.」
Expansion of the product lineup and development pipeline through partnering progressed to obtaining marketing approval for Lyfnua. - FY2022-Q2AdvancedAnnual report
「As part of efforts to expand the development pipeline, in April of the same year Kyorin Pharmaceutical Co., Ltd. entered into an agreement to acquire exclusive sales rights in Japan for gefapixant citrate, a treatment for chronic cough for which MSD Co., Ltd. had filed an application for marketing approval.」
Expansion of the pipeline through licensing and partnering progressed to the execution of an agreement to acquire exclusive domestic sales rights for gefapixant. - FY2021-Q2AdvancedAnnual report
「Under this agreement, Kyorin Pharmaceutical Co., Ltd. paid Aska Pharmaceutical Co., Ltd. an upfront payment and recorded it as research and development expenses. We will continue to actively pursue partnering activities, expand the development pipeline, and maximize the value of internally discovered products.」
Expansion of the development pipeline through partnering activities took concrete form in the co-development and commercialization agreement for AKP-009. - FY2021-Q1AdvancedAnnual report
「Compound for sensorineural hearing loss | Otonomy, Inc., United States | Upfront payment | Development milestones | Sales milestones | Royalties at a specified rate | 2020 | From the date the agreement was executed until the obligation to pay royalties ends」
As part of the expansion of the development pipeline through licensing activities, an out-licensing agreement was added with Otonomy, Inc. in the United States for a compound for sensorineural hearing loss. - FY2020-Q3AdvancedAnnual report
「Through licensing activities, the Group will continue working to expand its development pipeline.」
Expansion of the development pipeline through licensing activities took concrete form with the out-licensing of vibegron in South Korea and the in-licensing of ATYR1923 in Japan. - FY2019RestatedAnnual report
「We will continue to focus and prioritize drug discovery themes, pursue development of multilayered programs, and actively explore and in-license external drug discovery themes.」
We continue to expand the pipeline by focusing and prioritizing drug discovery themes, pursuing multilayered development, and exploring and in-licensing external themes. - FY2019-Q2AdvancedAnnual report
「Out-licensing to a foreign company; product: imidafenacin; Faes Farma; Spain; consideration: upfront fee, development milestones and sales milestones; contract year: 2018; term: 10 years from launch, automatically renewable.」
The out-licensing agreement with a Spanish company for imidafenacin marked the materialization of licensing activities in Europe. - FY2019-Q1RestatedAnnual report
「We will continue to make steady progress toward first-in-class drug discovery by further focusing and prioritizing our drug discovery themes, pursuing development of multilayered programs, and actively exploring and in-licensing external drug discovery themes.」
We continue to focus and prioritize drug discovery themes and explore and in-license external drug discovery themes to expand the pipeline in priority areas. - FY2018AdvancedAnnual report
「Through proactive licensing activities, we are working to expand the product lineup in the focus areas of respiratory medicine, otolaryngology and urology,」
Licensing activities aimed at expanding the product lineup in the 3 focus areas took concrete form through the acquisition of exclusive rights to KRP-N118. - FY2017RestatedAnnual report
「Through proactive licensing activities, our group is working to expand its product lineup in the focus areas of respiratory medicine, otolaryngology and urology, and continues to aim to establish a strong presence in these areas.」
We continue proactive licensing activities to expand the product lineup in the focus areas. - FY2017-Q3RestatedAnnual report
「While pursuing active licensing activities, we aim to expand our product lineup in the priority therapeutic areas (respiratory medicine, otolaryngology and urology) and enhance our presence in these areas.」
We continue proactive licensing activities as a means of expanding the product lineup and enhancing our presence in the focus areas. - FY2017-Q2First statedAnnual report
「The Group will pursue active licensing activities, expand its product offerings in priority areas—respiratory medicine, otolaryngology and urology—and work to enhance its presence in these areas.」
Active licensing is identified as a means of expanding product offerings and strengthening the Group’s presence in the 3 priority areas.